Status
Conditions
Treatments
About
The Quality of Life of patients treated with hadrontherapy is still limited. Two cohorts are established, they will be receiving specific standardized questionnaires to be evalutaed in their results.
Full description
Since 2011, CNAO has been treating patients suffering from solid tumors with particle therapy (both protons and carbon ions). Hadrontherapy improves outcome of radioresistant tumors which normally do not benefit from conventional radiotherapy. The treated population is highly heterogenous in term of tumor site, histotype, treatment fields and doses however its common anatomical origin justifies a unified approach in evaluating a QoL in this setting. QoL of patients suffering from these tumors have been poorly investigated and there are still few studies on patient reported outcomes (PROs) and QoL following hadrontherapy. In this context, therefore, there is a need to generate data by designing distinct cohort studies, conceived within a single protocol, that will gather quality of life data by means of standardized questionnaires of patients along their oncological history. Thanks to this protocol design, the investigator will be facilitated, in the future, in adding new cohorts pending a study protocol amendment and ethical approval.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Cohort A ("survivors"):
Inclusion Criteria
Exclusion Criteria:
Cohort B:
Inclusion Criteria:
Exclusion criteria:
180 participants in 2 patient groups
Loading...
Central trial contact
Anna Maria Camarda; Cristina Bono
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal